CYP19A1 and breast cancer: Among the four alleged molecular subtypes of breast cancer, the luminal subtype expresses ER and/or PR, which is a prognostic factor and predictive marker for anti-estrogen hormonal therapies, such as SERM or aromatase inhibitors.